

1 **Assessment of COVID-19 vaccine hesitancy among** 2 **Zimbabweans: A rapid national survey**

3

4
5 Paddington T. Mundagowa^{1*}¶, Samantha N. Tozivepi^{1¶}, Edward T. Chiyaka², Fadzai
6 Mukora-Mutseyekwa^{1,6}, Richard Makurumidze^{3,4,5,6}

7 **Affiliations**

- 8 1. Africa University, College of Health, Agriculture & Natural Science, Clinical
9 Research Centre
- 10 2. Kent State University, College of Public Health, Ohio, USA
- 11 3. University of Zimbabwe, Faculty of Medicine and Health Sciences, Public and
12 Global Health Unit, Harare, Zimbabwe
- 13 4. Institute of Tropical Medicine, Clinical Sciences Department, Antwerp, Belgium
- 14 5. Free University of Brussels (VUB), Gerontology, Faculty of Medicine &
15 Pharmacy, Brussels, Belgium
- 16 6. Zimbabwe College of Public Health Physicians, Harare, Zimbabwe

17

18 ***Corresponding Author:** Email: mundagowap@africau.edu (PTM)

19 ¶ PTM and SNT contributed equally.

20

21

22 Abstract

23 **Background:** To minimise the devastating effects of the coronavirus disease 2019
24 (COVID-19) pandemic, scientists hastily developed a vaccine. However, the scale-up of
25 the vaccine is likely to be hindered by the widespread social media misinformation. We,
26 therefore, conducted a study to assess the COVID-19 vaccine hesitancy among
27 Zimbabweans.

28 **Methods:** We conducted a descriptive online cross-sectional survey using a self-
29 administered questionnaire among adults. The questionnaire assessed willingness to be
30 vaccinated; socio-demographic characteristics, individual attitudes and perceptions,
31 effectiveness, and safety of the vaccine. Multivariable logistic regression analysis was
32 utilized to examine the independent factors associated with vaccine uptake.

33 **Results:** We analysed data for 1168 participants, age range of 19-89 years with the
34 majority being females (57.5%). Half (49.9%) of the participants reported that they
35 would accept the COVID-19 vaccine. The majority were uncertain about the
36 effectiveness of the vaccine (76.0%) and its safety (55.0%). About half lacked trust in
37 the government's ability to ensure the availability of an effective vaccine and 61.0%
38 mentioned that they would seek advice from a healthcare worker to vaccinate. Age 55
39 years and above [vs 18-25 years - Adjusted Odds Ratio (AOR): 2.04, 95% Confidence
40 Interval (CI): 1.07-3.87], chronic disease [vs no chronic disease - AOR: 1.72, 95%CI:
41 1.32-2.25], males [vs females - AOR: 1.84, 95%CI: 1.44-2.36] and being a healthcare
42 worker [vs not being a health worker – AOR: 1.73, 95%CI: 1.34-2.24] were associated
43 with increased likelihood to vaccinate. History of COVID-19 infection [vs no history -

44 AOR: 0.45, 95%CI: 0.25-0.81) and rural residence [vs urban - AOR: 0.64, 95%CI: 0.40-
45 1.01] were associated with reduced likelihood to vaccinate.

46 **Conclusion:** We found half of the participants willing to vaccinate against COVID-19.
47 The majority lacked trust in the government and were uncertain about vaccine
48 effectiveness and safety. The policymakers should consider targeting geographical and
49 demographic groups which were unlikely to vaccinate with vaccine information,
50 education, and communication to improve uptake.

51

52 **Keywords:** COVID-19, coronavirus, vaccine, hesitancy, willingness, Zimbabwe

53 Introduction

54 Since the first case of the coronavirus disease (COVID-19) caused by the novel severe
55 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in 2019, more
56 than three million fatalities and 1.55 billion cases have been recorded globally (1) The
57 healthcare systems have been strained and the adverse socio-economic and
58 psychological impacts are overwhelming (2–4).

59 Fortunately, more than 100 vaccines have gone beyond the pre-clinical development
60 phase with more than half of these reaching the clinical development phase (5). The
61 herd immunity for SARS-CoV-19 can be reached by vaccinating about 60-72% of the
62 population (6), thus, vaccine acceptance rates will play a major role in combating the
63 pandemic. However, vaccine hesitancy has been recognized as a major threat to the
64 control of vaccine preventable diseases (7). The recent COVID-19 pandemic has
65 caused an outbreak of “infodemics” which has led to rapid and far-reaching spread of

66 inaccurate information on the COVID-19 vaccine (8). This deluge of unreliable
67 information can contribute to COVID-19 vaccine hesitancy despite the availability of
68 safe and effective vaccines (9).

69 Like many other developing countries, Zimbabwe has started the process of securing
70 COVID-19 vaccine. A COVID-19 national deployment and vaccination strategy (10) has
71 been developed and plans for national deployment and training of healthcare workers
72 are underway. In this barrage of infodemics, Zimbabweans have not been spared as
73 conspiracy beliefs filtered through the population, particularly through the different social
74 media platforms. The best way to fight misinformation is through aggressive
75 dissemination of accurate information about the truths of the risks and benefits of
76 COVID-19 vaccine.

77 Evidence on the population's intention to be vaccinated for COVID-19 is limited and
78 public health authorities are confronted with a challenge of objectively discerning the
79 truth from the circulating information blast. Understanding the factors influencing
80 vaccine hesitancy is pertinent in crafting targeted communication and interventions to
81 sell the idea of vaccination to specific groups of people. We therefore conducted a
82 national survey to assess COVID-19 vaccine hesitancy among Zimbabweans. We
83 assessed socio-demographic characteristics, individual attitudes and perceptions,
84 Covid-19 vaccine effectiveness and safety, and risks of contracting the COVID-19 in
85 relation to the uptake of the COVID-19 vaccine.

86 **Methods**

87 **Study Design**

88 We conducted an online descriptive cross-sectional survey in February 2021.

89 **Study setting**

90 The study was conducted in Zimbabwe. By the end of 2020, the country had an
91 estimated population of 15.1 million (11). Approximately 99.6% of the population is of
92 African origin and the median age is 18.7 years (12). Geographically, the country is
93 divided into 10 provinces and 63 districts. The first COVID-19 case was recorded on the
94 20th of March 2020 and according to the Zimbabwean Ministry of Health and Child Care
95 Daily COVID-19 Update Report of the 11th of May 2021, the country had recorded a
96 cumulative of 38 466 cases, 36 277 recoveries, and 1579 deaths (13).

97 **Study participants**

98 All Zimbabwean residents were eligible to participate in the survey. Considering the
99 online nature of the survey and the easy sharing via social networks, we allowed
100 Zimbabweans out of the country to participate but were excluded from the analysis
101 because (information to inform local context) their COVID-19 vaccine uptake was more
102 likely to be influenced by their current context. We included adults aged 18 years and
103 above and those who had participated but below 18 years were excluded. The survey
104 was disseminated mainly via social media networks (WhatsApp and Facebook) hence
105 those registered in those platforms were likely to participate.

106

107 **Sample size**

108 The minimum sample size was estimated at 423, based on the following assumptions;
109 95% confidence interval, 5% margin of error, the expected proportion of vaccine uptake
110 estimated as 52% (14) in the adult population in Zimbabwe and the attrition rate of 10%.

111 **Data collection tools and procedures**

112 A multi-item survey questionnaire was developed based on literature review (15,16).
113 The online questionnaire was designed using Google Forms. The survey questionnaire
114 was developed in English and later translated into the two main local languages in
115 Zimbabwe, Shona and Ndebele. The survey questionnaire comprised of five sections
116 with the first section collecting participant's demographic data (age, sex, residence,
117 educational level, employment status, medical aid status). The second section
118 consisted of questions soliciting information and knowledge on COVID-19 vaccine. The
119 third section sought to assess vaccine uptake, effectiveness and safety. The fourth
120 section assessed the risk of contracting COVID-19. We also collected qualitative
121 information through open-ended questions and will be reported separately.

122 Our outcome variable was vaccine uptake in the event that a COVID-19 vaccine
123 becomes available and it had three responses, "Would Accept", "Unsure" and "Would
124 reject". However, for our analysis we combined our responses into binary those that will
125 be vaccinated "Yes" (Would Accept) and those that would not be vaccinated, "No"
126 (Unsure/Would reject). Potential study participants were recruited using random
127 sampling via social media mainly WhatsApp and Facebook through the network and

128 contacts of the researchers. The researchers encouraged participants to share the
129 online survey with others in their networks as well. The survey was also shared in social
130 media groups for academic and community organizations. Measures were put in place
131 to ensure that the questionnaire was taken only once. Data were collected over a period
132 of 15 days from the 3rd of February 2021 to the 17th of February 2021.

133

134 **Statistical Analysis**

135 A database was created in Microsoft Excel using the data extracted from the online
136 server. Responses from the Shona and Ndebele questionnaires were coded into
137 English and then merged into one English database. Data cleaning was done in Excel
138 before exporting it to SPSS for analyses. Statistical analysis was performed using SPSS
139 (V.26.0). Descriptive statistics were conducted using frequencies and proportions and
140 were presented in tables and graphs. Logistic regression models were used to examine
141 factors associated with vaccine uptake. Statistical significance was set at $p < 0.05$ and
142 95% confidence interval.

143 **Ethical considerations**

144 Ethical clearance to carry out this study was obtained from the Medical Research
145 Council of Zimbabwe (MRCZ/A/2714). Informed consent was provided online and all
146 participants were asked to accept or reject participation in the online survey.
147 Participation in this study was voluntary and was not incentivized. All the responses
148 provided during this survey were anonymous.

149 **Results**

150 **Study participants**

151 We received 1290 responses during the survey period. In terms of language, the
152 distribution of responses was as follows: 1196 English, 71 Shona and 23 Ndebele. Of
153 the 1290 participants who completed the survey, 122 were excluded from analysis for
154 the following reasons (89 were based outside Zimbabwe, 4 were under the age of 18
155 years, 26 were duplicate responses, and in 3 age was missing). We finally analysed
156 1168 participants. The study participants were from all the 10 provinces of Zimbabwe
157 and half (50.5%) were from Harare province which houses the capital city of the
158 country.

159 **Socio-demographic characteristics of the study participants**

160 A total of 1168 participants were included in the study with a median age of 39 years
161 (interquartile range; IQR: 32-49) and an age range of 19 – 89 years. Table 1 shows a
162 summary of the socio-demographic characteristics of the participants. The majority of
163 the study participants were in the 36-45 years age group. Females constituted (57.5%)
164 while 36% were health care workers. A significantly higher proportion (92.6%) of
165 participants was residing in an urban setting. About 41.2% of the participants reported
166 having at least one chronic condition. More than 90% reported having a good health
167 status and a similar proportion had tertiary education as the highest level of education
168 achieved. About 5% reported having tested positive for COVID-19 at some point prior to
169 the survey. Among health care workers, only 6% of them reported having been

170 diagnosed of COVID-19 prior to the survey. Additionally, about 37.9% of health care
 171 workers reported having at least one chronic condition (results not shown in the table).
 172 Table 1 shows a summary of the socio-demographic characteristics of the participants.

173 **Table 1. Socio-demographic characteristics of survey participants (N = 1,168)**

Characteristics	n (%)	Vaccine uptake	
		Yes (n = 579)	No (n = 589)
Age group (years)			
18-25	125 (10.7)	53 (42.4)	72 (57.6)
26-35	308 (26.4)	141 (45.8)	167 (54.2)
36-45	365 (31.3)	186 (51.0)	179 (49.0)
46-55	214 (18.3)	109 (50.9)	105 (49.1)
>55	156 (13.4)	90 (57.7)	66 (42.3)
Sex			
Male	496 (42.5)	280 (56.5)	216 (43.5)
Female	672 (57.5)	299 (44.5)	373 (55.5)
Health care worker			
Yes	420 (36.0)	234 (55.7)	186 (44.3)
No	748 (64.0)	345 (46.1)	403 (53.9)
Chronic conditions			
Yes	481 (41.2)	276 (57.4)	205 (42.6)
No	687 (58.8)	303 (44.1)	384 (55.9)
Health status			
Good	1054 (90.2)	520 (49.3)	534 (50.7)
Not so good	114 (9.8)	59 (51.8)	55 (48.2)
Tertiary education			
Yes	1102 (94.3)	547 (49.6)	555 (50.4)
No	66 (5.7)	32 (48.5)	34 (51.5)
Residence			
Urban	1081 (92.6)	544 (50.3)	537 (49.7)
Rural	87 (7.4)	35 (40.2)	52 (59.8)
Employment status			
Employed	955 (81.8)	465 (48.7)	490 (51.3)
Not employed	103 (8.8)	58 (56.3)	45 (43.7)
Student	110 (9.4)	56 (50.9)	54 (49.1)
Medical Aid			
Yes	922 (78.9)	460 (49.9)	462 (50.1)
No	246 (21.1)	119 (48.4)	127 (51.6)
Medical Home			
Yes	895 (76.6)	458 (51.2)	437 (48.8)

No	273 (23.4)	121 (44.3)	152 (57.7)
Telehealth access			
Yes	665 (56.9)	341 (51.3)	324 (48.7)
No	503 (43.1)	238 (47.3)	265 (52.7)
Got COVID19			
Yes	57 (4.9)	19 (33.9)	38 (66.7)
No	1111 (95.1)	560 (50.4)	551 (49.6)

174 Uptake of the vaccine

175 Half (49.9%) of the participants indicated that they would accept the COVID-19 vaccine
 176 if they are offered when it becomes available, about 31.1% were unsure of whether they
 177 would take the vaccine or not and the other 19% indicated that they would reject the
 178 vaccine outright. The proportion of vaccine uptake across the different age groups
 179 differed. Among adults aged 55 years and older, about 57.9% were willing to get
 180 vaccinated compared to only 43.9% in the 18-25 years age group. Among health care
 181 workers, 56.3% reported having an intention to get vaccinated. Additionally, 57.9% of
 182 those who reported having at least one chronic condition expressed willingness to get
 183 vaccinated once the vaccine was available. Participants with a tertiary education were
 184 indifferent about vaccination with 50% expressing interest. After combining responses
 185 on our outcome variable, half (49.9%) of the study participants would accept the
 186 vaccine, “Yes” (Would Accept) and the other half (50.1%) would not be vaccinated, “No”
 187 (Unsure/Would reject).

188 Risk of contracting the COVID-19 infection

189 Among those who had been previously diagnosed of COVID-19, about 37% indicated
 190 that their infection was not so severe, while the other 14% did not experience any

191 severe symptoms due to the infection. Additionally, about 37% indicated that they were
192 not worried of the possibility of re-infection by the virus. Approximately 77% of the
193 participants were worried about the possibility that they might contract the virus, while
194 91% were worried about the possibility that a friend or a relative might catch the virus.
195 Fig 1 shows the perceived risk of contracting COVID-19.

196 **Fig 1. Risk of contracting COVID-19**

197 **Perceived vaccine effectiveness and safety of the COVID-19 vaccine**

198 Approximately 76% of the participants did not think that the vaccine will be effective in
199 reducing symptoms of the virus and another 72% indicated that they did not think that
200 the vaccine will be effective in preventing infection. Slightly more than half (51%) of the
201 participants indicated that they did not trust the government and other relevant
202 authorities in ensuring that the vaccine is effective and safe. Fig 2 shows the perceived
203 effectiveness and safety of the COVID-19 vaccine.

204 **Fig 2. Perceived vaccine effectiveness and safety of the COVID-19 vaccine**

205 **Decision to be vaccinated with the COVID-19 vaccine**

206 Among factors considered by participants in deciding to get vaccinated or not, we
207 looked at convenience, availability, confidence in vaccine efficacy, vaccine
208 effectiveness, and potential sources of advice. About 58% of the adults indicated that
209 they would strongly consider vaccine effectiveness in their decision-making process. A
210 similar proportion also identified free vaccine access and vaccine safety as important

211 factors in deciding whether to get vaccinated for COVID-19 or not. Fig 3 shows the
212 preferences of the adults on the different factors assessed.

213 **Fig 3. Decision to be vaccinated with the COVID-19 vaccine**

214 **Factors associated with intention to be vaccinated with the COVID-19** 215 **vaccine**

216 Different covariates were assessed on their association with intention to vaccinate using
217 logistic regression analysis (Table 2). After adjusting for all covariates of interests,
218 adults aged 55 years and older were two times more likely to get vaccinated when
219 compared to those aged 18-25 years [Adjusted Odds Ratio (AOR): 2.04, 95% CI: (1.07
220 – 3.87)]. Similarly, health care workers were 1.73 times more likely to get vaccinated
221 when compared to non-health care workers [AOR: 1.73, [95% CI: (1.34 – 2.24)]. Being
222 male [vs female AOR: 1.84, 95% CI: (1.44 – 2.36)] and having at least one chronic
223 condition [vs no chronic condition AOR: 1.72, 95% CI: (1.32 – 2.25)] were significantly
224 associated with intention to vaccinate. Participants who had been previously diagnosed
225 of COVID-19 [vs no previous COVID-19 infection AOR: 0.45, 95% CI: (0.25 – 0.81)]
226 were significantly less likely to get vaccinated. Not so good health status, tertiary
227 education, and medical home (having a primary health care doctor) were associated
228 with borderline likelihood of getting vaccinated. We assessed the same covariates
229 among the health care workers sub group, and only being male [vs females, AOR: 1.92
230 95% CI: (1.24 – 2.98)] was associated the likelihood of getting vaccinated.

231 **Table 2. Bivariate and multivariable logistic regression model results**

	Unadjusted Odds Ratio (UOR) and 95% CI		Adjusted Odds Ratio (AOR) and 95% CI	
	UOR	95% CI	AOR	95% CI
Age group (years)				
18-25	Ref		Ref	
26-35	1.15	0.75 – 1.75	1.57	0.89 – 2.75
36-45	1.41	0.94 – 2.13	1.84	1.04 – 3.28
46-55	1.41	0.90 – 2.20	1.75	0.95 – 3.23
>55	1.85	1.15 – 2.98	2.04	1.07 – 3.87
Sex				
Female	Ref		Ref	
Male	1.62	1.28 – 2.04	1.84	1.44 – 2.36
Health care worker				
No	Ref		Ref	
Yes	1.47	1.16 – 1.87	1.73	1.34 – 2.24
Chronic conditions				
No	Ref		Ref	
Yes	1.71	1.35 – 2.16	1.72	1.32 – 2.25
Health status				
Good	Ref		Ref	
Not so good	0.91	0.62 – 1.34	1.13	0.74 – 1.72
Tertiary education				
No	Ref		Ref	
Yes	1.05	0.64 – 1.72	1.13	0.66 – 1.91
Residence				
Urban	Ref		Ref	
Rural	0.66	0.43 – 1.04	0.64	0.40 – 1.01
Employment status				
Not employed	Ref		Ref	
Student	0.81	0.47 – 1.38	1.24	0.63 – 2.43
Employed	0.74	0.49 – 1.11	0.63	0.40 – 0.99
Medical Aid				
No	Ref		Ref	
Yes	1.06	0.80 – 1.41	0.91	0.65 – 1.25
Medical Home				
No	Ref		Ref	
Yes	1.32	1.00 – 1.73	1.20	0.87 – 1.64
Telehealth access				
No	Ref		Ref	
Yes	1.17	0.93 – 1.48	1.18	0.92 – 1.51
Got COVID19				
No	Ref		Ref	
Yes	0.49	0.28 – 0.86	0.45	0.25 – 0.81

Statistical significance at 5% alpha is indicated by odds ratios in bold, CI: confidence interval, Ref: reference

category

232 .

233

234 **Discussion**

235 Our study was the first to assess the COVID-19 vaccine hesitancy at national level in
236 Zimbabwe. The study findings showed that half of the study participants reported that
237 they would accept the COVID-19 vaccine if it becomes available. The majority of the
238 survey participants were uncertain about the effectiveness of the vaccine and lacked
239 confidence on the safety of the vaccine. About half lacked trust in the government's
240 ability to ensure that the vaccine will be effective and most participants would seek the
241 advice of a healthcare worker first before getting vaccinated. Increased age, presence
242 of chronic disease/condition, male gender and being a healthcare worker were
243 associated with increased likelihood of vaccine acceptance while a history of COVID-19
244 infection and rural residence were associated with reduced likelihood of vaccine
245 acceptance.

246 Our study findings showed that half of the participants (50%) were willing to take the
247 COVID-19 vaccine while the other half were either unsure or would reject taking the
248 vaccine. These findings are consistent with other African studies from the Democratic
249 Republic of Congo (DRC) (56%) (17), and Nigeria (50%) (18). The similarities in
250 findings may be due to resemblances in the methodology used, as well as socio-
251 economic and political settings in DRC, Nigeria and Zimbabwe. However, a South
252 African survey showed that about 71% were willing to get vaccinated against COVID-19
253 (19). Based on the significant difference in vaccine acceptance for this study and the

254 South African study, one might hypothesize that South Africans were more likely to
255 accept the vaccine given the high numbers of reported COVID-19 cases and fatalities
256 as compared to the other countries (DRC, Nigeria and Zimbabwe).

257 Moreover, the surveys from DRC, Nigeria and this study were conducted before the
258 vaccine was rolled out and conspiracy theories on the COVID-19 vaccine were at their
259 peak thus, the researchers predict an increase in vaccine acceptance as more accurate
260 information penetrates the population, more people getting vaccinated and vaccine
261 effectiveness being witnessed in those who would have been vaccinated. The level of
262 vaccine hesitancy found in our study was low when compared to the required COVID-19
263 herd immunity i.e. 60-70% (20). A COVID-19 vaccine uptake of 50% may not be
264 adequate based on Zimbabwean government's plans to vaccinate 60% of the
265 population as a way of reaching the herd immunity threshold (21). Therefore, there is a
266 need to come up with strategies to increase the proportion of citizens willing to get the
267 COVID-19 vaccine. Strategies that have been shown to increase COVID-19 vaccine
268 uptake include engagement of community leaders, social mobilization tactics, mass
269 media campaigns, the use of reminder and follow-up systems, training and education of
270 health care professionals, incentives, vaccine mandates, efforts to make vaccine more
271 accessible, and efforts to increase general knowledge and awareness (22,23).

272 Healthcare workers who took part in this study were more likely to accept the COVID-19
273 vaccine and this finding corroborated with a study in the U.S (24). It can be
274 hypothesised that healthcare workers perceived their susceptibility to contract COVID-
275 19 as high as evidenced by a study which reported that healthcare workers had a more
276 than seven-fold higher risk of severe COVID-19 across all occupational groups (25).

277 Since health providers have the moral obligation not to harm their patient (26), they may
278 feel compelled to protect the sick and vulnerable patients by getting vaccinated
279 themselves. This is a decisive finding since healthcare workers' vaccine acceptance can
280 easily untangle vaccine hesitancy when recommending the vaccine to their clients. The
281 health providers can also serve as role models of vaccine acceptance for the general
282 population. Efforts to combat COVID-19 vaccine hesitancy among the general
283 population can utilize the increased intention to vaccinate among health workers by
284 making them community outreach vaccine advocates.

285 Most of the study participants doubted the effectiveness of the COVID-19 vaccine. This
286 was consistent with findings from an African study where despite the respondents'
287 agreement with the importance of vaccinating the population against SARS-CoV-2,
288 many had reservations about the effectiveness and safety of the vaccine (27). The
289 doubting of the effectiveness could be attributed to several reasons. Firstly, this could
290 be attributed to the lack of information on how the vaccine was developed and tested.
291 There has been concern on how some vaccines were developed with people preferring
292 those thought to have been developed transparently in comparison to those whose
293 development was shrouded with secrecy (28,29). Secondly, there were concerns on
294 whether trials were not rushed and regulatory standards relaxed considering the
295 unprecedented speed at which the COVID-19 vaccines were developed (30). The lack
296 of lucid information on vaccine development exacerbates the vaccine hesitancy problem
297 and it is essential for health authorities to be equipped with authentic information on
298 how the COVID vaccines were developed; thus enabling them to disseminate factual
299 information and allay the vaccine effectiveness related anxieties.

300 The perceived lack of acceptance of the COVID-19 vaccine in Zimbabwe can partly be
301 attributed to earlier reports on safety of the COVID-19 vaccines with respect to possible
302 side- and adverse effects (31). Some Zimbabweans became sceptical and reserved
303 towards the vaccine especially after experts questioned the effectiveness of the
304 vaccines developed before the 501.V2 coronavirus variant which originated from South
305 Africa and appeared to be a more contagious strain infiltrating the country (21). The
306 widespread dissemination of vaccine safety information should be done before rolling
307 out the vaccine to ensure that people make an informed decision based on scientifically
308 proven information instead of rumours and conspiracy theories. The health authorities
309 should continue to update citizens about vaccine side-effects and institute strong
310 pharmacovigilant systems as well as, compensation schemes for severe adverse
311 events as this might boost public confidence in vaccine safety (32,33).

312 About half of the participants in this study lacked trust on whether the government and
313 relevant authorities would be able to provide a safe vaccine that would protect them
314 from COVID-19. Such public insecurities were also observed in other studies on vaccine
315 hesitancy (34,35). These public insecurities may be caused by unsubstantiated political
316 statements, incapacities of the health system and centralisation of health services.
317 Unscientific claims on COVID-19 by individuals in positions of authority can introduce
318 uncertainties within the population and lower their trust in how the government is
319 handling the pandemic. The Zimbabwean healthcare system is facing serious
320 challenges including shortage of essential drugs, lack of equipment to carry out basic
321 procedures, and skills migration thus, citizens may lack trust in the system's ability to
322 contain the pandemic. Despite the proposed free COVID-19 vaccination, there are other

323 indirect costs that could be incurred by citizens to get to the vaccination sites which are
324 currently centralised at secondary and tertiary health facilities. Travelling costs and loss
325 of productive time could be potential barriers to COVID-19 vaccination in low-income
326 settings like Zimbabwe. Thus, the government should work towards increasing the
327 national health budget to cater for the excess service demand caused by the pandemic.
328 It is also critical to decentralize vaccination sites and to use influential community
329 leaders for community outreach activities.

330 The current study also revealed that an increase in age and the presence of a chronic
331 condition were associated with a high likelihood of vaccine acceptance. These findings
332 are consistent with findings from other studies that showed a strong association
333 between age and willingness to get vaccinated (35,36). The risk of severe COVID-19
334 increases with age and 80% of COVID-19 deaths are of adults 65 years and older (37).
335 Additionally, multiple chronic conditions complicate the progression of COVID-19 (38).
336 Thus, the elderly and those with chronic conditions may have increased perceived
337 vulnerability to the disease and are more likely to take steps towards protecting
338 themselves.

339 We noted that males were more likely to accept the vaccine. Several other studies also
340 revealed similar results (27,28,39–41). This was an unexpected finding given the poor
341 health seeking behaviour among men (42). However, men constitutes the highest
342 proportion of the Zimbabwean workforce and the speculations that some organisations
343 might prioritise or mandate vaccination among their employees to continue productivity
344 in wake of anticipated lockdowns might have influenced men's decision. The reduced
345 vaccine acceptance among women can be attributed to a lack of information of the

346 safety of the vaccine especially with regards to conception related matters; however
347 experts believe that the vaccines were unlikely to pose a risk to pregnant and lactating
348 woman (43). The finding that among the health care worker subgroup, males were also
349 likely to be vaccinated than females can be explained by some of the reasons
350 discussed above. Health authorities have the responsibility to give women updated
351 information on the safety of the vaccine during the community outreach activities. It was
352 surprising to note that 39% of those who reported previous COVID-19 infection in this
353 study were less likely to be vaccinated. This is despite the fact that those with a history
354 of prior infection could be reinfected by SARS-CoV-2 even after recovering from the
355 initial infection (44). Studies have shown that primary infection only provides short term
356 protective immunity against SARS-CoV-2 (45–47). Individuals who would have
357 recovered from coronavirus infection may perceive their susceptibility as low assuming
358 that they would have garnered natural immunity. Although those who have been
359 previously infected by SARS-CoV-2 are less likely to have a repeat infection when
360 compared to those without evidence of previous infection, they are still susceptible to
361 reinfection (48), hence, the need to be vaccinated as well.

362 The present study noted that rural residents were less likely to pursue COVID-19
363 vaccination when compared to those residing in urban areas. This finding corroborates
364 with findings from other similar studies (28,34,49). This could be attributed to poor
365 information penetration and reduced perceived susceptibility risk among the rural folks.
366 The finding can also be explained by the fact that rural residents have reduced health
367 literacy and awareness, reduced trust and interaction with healthcare workers, and
368 presumed cost-based concerns (34,50,51). Information travels faster in urban areas

369 where mass media and internet connection are readily available thus, it can be easier
370 for those residing in urban areas to access authentic information about the vaccine
371 when compared to most remote rural areas in Zimbabwe. This shows the importance of
372 tailoring vaccine awareness strategies relative to populations residing in varying
373 geographical regions. The authors recommend that policy makers consider
374 geographical- and socio-cultural-specific information for education and communication
375 when approaching the diverse residential settings.

376 **Strengths and limitations**

377 Our study assessed a broad range of factors that have been known to influence vaccine
378 acceptance. The findings can be used to guide future health activities with an aim of
379 improving COVID-19 vaccine uptake or uptake of other vaccines. All the ten
380 Zimbabwean provinces were represented although some were more represented than
381 others. The data collection tools were distributed in all the three common languages
382 used in Zimbabwe to accommodate the majority of citizens. The study received a fairly
383 good response rate, which was unexpected by the researchers given that no incentives
384 were given to cover internet connection fees. The increased use of internet services
385 during the COVID-19 era enabled swift and cost effective online data collection on the
386 part of the researchers.

387 Despite the relatively large sample size, the generalizability of our findings can be
388 hampered by our sampling method. The researchers used mainly their social media
389 networks as proxies for distributing the data collection tool. The study was also limited
390 to those who had access to mobile phones, tablets, or computers, thus introducing a

391 selection bias. We may have excluded the poor and the old who in fact are vulnerable
392 to COVID-19. Besides, the data were collected before the vaccine was rolled out in the
393 country and vaccine hesitancy may have waned as more authentic information became
394 available to the population. The participants were mostly urban dwellers with easy
395 access to internet connection and this could have potentially resulted in a selection bias
396 leaving the rural population. The fact that this study utilized self-reported data makes it
397 vulnerable to reporting bias.

398 There is a need for further studies to understand how COVID-19 vaccine hesitancy will
399 evolve with time. With the COVID-19 vaccine now available in the country and already
400 being given, studies should be conducted periodically to assess the time-sensitive
401 aspect of the vaccine hesitancy among those who rejected the vaccine or were unsure
402 of it. Our study reported the quantitative findings associated with COVID-19 vaccine;
403 there is therefore a need for qualitative studies to explore contextual and other
404 individual factors that lead to vaccine hesitancy. Since in our study we were unable to
405 report vaccine hesitancy among targeted sectors of the populations e.g. education,
406 commerce, tourism among others, studies are required to assess how vaccine
407 hesitancy will vary across these sectors. These will enable targeted messaging to
408 improve the vaccine uptake. Though we assessed vaccine hesitancy among health care
409 workers, we were unable to disentangle our data to find out hesitancy among various
410 groups of healthcare workers. Future studies looking into vaccine hesitancy among
411 health care workers should be in position to assess vaccine hesitancy among doctors,
412 nurses, pharmacists and many other healthcare worker professionals. To try and be
413 more representative, especially inclusion of the rural communities, future studies should

414 be conducted physically so that the barrier of access to internet and electronic gadgets
415 can be bridged. However, strategies to mitigate against COVID-19 infection and spread
416 should be observed.

417 **Conclusions**

418 In our study, we found half of the participants were willing to get vaccinated against
419 COVID-19 with the majority lacking trust in the government and being uncertain about
420 vaccine effectiveness and safety. The high vaccine acceptance among health workers
421 and the finding that the majority will consult health care workers before deciding to
422 vaccinate, can be a good foundation to launch a successful COVID-19 vaccine
423 awareness campaign in the country. However, the level of vaccination uptake is way
424 below the expected herd immunity hence the government and other relevant authorities
425 should provide timely and accurate information through community-wide campaigns.
426 Strategies should also be put in place to target and prioritise groups likely not to
427 vaccinate such as females, younger ages and those without chronic conditions. The
428 government and other relevant authorities should aim for a more transparent strategy
429 since it will contribute to public trust and increased acceptability of the vaccine.

430 **Acknowledgements**

431 The authors would like to thank the following organisations for the support during the
432 study; the University of Zimbabwe, Faculty of Medicine and Health Sciences, Global
433 and Public Health Unit, Africa University, College of Health, Agriculture & Natural
434 Science, Clinical Research Centre (AUCRC) and the Zimbabwe College of Public

435 Health Physicians (ZCPHP). The authors would like to thank the following individuals
436 Mandla Tirivavi from AUCRC for administrative support, Brian Maponga and Pamela
437 Magande from the ZCPHP for facilitating the distribution of the survey and ethical
438 approval. Finally, we thank all the Zimbabweans who participated in the survey.

439 Authors Contributions

Author	Contribution
Paddington T. Mundagowa	Conceptualisation, Methodology, Investigation, Validation, Writing – original draft preparation, Writing – review & editing
Samantha N. Tozivepi	Conceptualisation, Methodology, Investigation, Data curation, Validation, Writing – original draft preparation, Writing – review & editing
Edward T. Chiyaka	Conceptualisation, Methodology, Formal Analysis, Validation, Writing – original draft preparation, Writing – review & editing
Fadzai Mukora-Mutseyekwa	Conceptualisation, Methodology, Project administration, Supervision, Resources, Funding Acquisition, Writing – review & editing
Richard Makurumidze	Conceptualisation, Methodology, Investigation, Validation, Project administration, Supervision, Writing – original draft preparation, Writing – review & editing

440 Declarations

441 Data Availability

442 The data used during analysis is available from the corresponding author upon a
443 reasonable request.

444 **Funding**

445 The study received funding for ethical approval from the Africa University, College of
446 Health, Agriculture & Natural Science, Clinical Research Centre. The funders had no
447 role in study design, data collection and analysis, decision to publish, or preparation of
448 the manuscript.

449 **Competing Interests**

450 The authors declare that they have no competing interests.

451 **References**

- 452 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. 2021 [cited 2021 May
453 28]. Available from: <https://covid19.who.int/>
- 454 2. Jahanshahi AA, Dinani MM, Madavani AN, Li J, Zhang SX. The distress of Iranian
455 adults during the Covid-19 pandemic – More distressed than the Chinese and
456 with different predictors. *Brain Behav Immun* [Internet]. 2020 Jul;87:124–5.
457 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0889159120307121>
- 458 3. Mukaetova-Ladinska EB, Kronenberg G. Psychological and neuropsychiatric
459 implications of COVID-19. *Eur Arch Psychiatry Clin Neurosci* [Internet]. 2021 Mar
460 22;271(2):235–48. Available from: [http://link.springer.com/10.1007/s00406-020-](http://link.springer.com/10.1007/s00406-020-01210-2)
461 01210-2

- 462 4. Morgantini LA, Naha U, Wang H, Francavilla S, Acar Ö, Flores JM, Crivellaro S,
463 Moreira D, Abern M, Eklund M, Vigneswaran HT WS. Factors contributing to
464 healthcare professional burnout during the COVID-19 Pandemic: A rapid
465 turnaround global survey. PLoS One. 2020;15(9).
- 466 5. WHO. Draft Landscape of COVID-19 Candidate Vaccines [Internet]. Geneva;
467 2021. Available from: [https://www.who.int/publications/m/item/draft-landscape-of-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
468 [covid-19-candidate-vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)
- 469 6. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd
470 immunity to SARS-CoV-2 infection by mass vaccination. Lancet [Internet]. 2020
471 Nov;396(10263):1614–6. Available from:
472 <https://linkinghub.elsevier.com/retrieve/pii/S0140673620323187>
- 473 7. WHO. Ten threats to global health in 2019 [Internet]. World Health Organization.
474 2019 [cited 2021 May 28]. Available from: [https://www.who.int/news-](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019)
475 [room/spotlight/ten-threats-to-global-health-in-2019](https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019)
- 476 8. WHO. Infodemic management- infodermiology [Internet]. World Health
477 Organization. 2020 [cited 2021 Jan 19]. Available from:
478 <https://www.who.int/teams/risk-communication/infodemic-messaging>
- 479 9. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. Vaccine
480 [Internet]. 2015 Aug;33(34):4161–4. Available from:
481 <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005009>
- 482 10. MoHCC. COVID-19 vaccination gets traction [Internet]. Ministry of Health and
483 Child Care, Zimbabwe. 2021 [cited 2021 Jan 19]. Available from:
484 http://www.mohcc.gov.zw/index.php?option=com_content&view=article&id=355:c

- 485 ovid-19-vaccination-gets-traction&catid=84&Itemid=435
- 486 11. Worldometer. Zimbabwe population 2021 [Internet]. Worldometer. 2021 [cited
487 2021 May 28]. Available from: [https://www.worldometers.info/world-](https://www.worldometers.info/world-population/zimbabwe-population/#:~:text=Zimbabwe 2020 population is estimated,year according to UN data.)
488 [population/zimbabwe-population/#:~:text=Zimbabwe 2020 population is](https://www.worldometers.info/world-population/zimbabwe-population/#:~:text=Zimbabwe 2020 population is estimated,year according to UN data.)
489 [estimated,year according to UN data.](https://www.worldometers.info/world-population/zimbabwe-population/#:~:text=Zimbabwe 2020 population is estimated,year according to UN data.)
- 490 12. ZIMSTAT. Census 2012 Preliminary Report. Harare; 2012.
- 491 13. Ministry of Health and Child Care(MoHCC). Situation report COVID-19,
492 Zimbabwe. Harare; 2021.
- 493 14. Topline Research Solutions. Zimbabweans opinion survey: How best to assist the
494 COVID 19 situation in Zimbabwe [Internet]. Harare; 2020. Available from:
495 [https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahU](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEWj5ieON1fTwAhWFGuwKHeoCBWlQFjABegQlAxAD&url=https%3A%2F%2Ftopliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvghxJPnqKi4xAlg)
496 [KEWj5ieON1fTwAhWFGuwKHeoCBWlQFjABegQlAxAD&url=https%3A%2F%2F](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEWj5ieON1fTwAhWFGuwKHeoCBWlQFjABegQlAxAD&url=https%3A%2F%2Ftopliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvghxJPnqKi4xAlg)
497 [opliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEWj5ieON1fTwAhWFGuwKHeoCBWlQFjABegQlAxAD&url=https%3A%2F%2Ftopliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvghxJPnqKi4xAlg)
498 [FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvghxJPnqKi4xAlg](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEWj5ieON1fTwAhWFGuwKHeoCBWlQFjABegQlAxAD&url=https%3A%2F%2Ftopliners.co.za%2Fwp-content%2Fuploads%2F2021%2F01%2FProject-Hondo-FINAL-Report-14-Jan-2021.pdf&usg=AOvVaw2pLvghxJPnqKi4xAlg)
- 499 15. Lin C, Tu P, Beitsch LM. Confidence and receptivity for covid-19 vaccines: A rapid
500 systematic review. *Vaccines*. 2021;9(1):1–32.
- 501 16. COVID Collaborative. Coronavirus Vaccine Hesitancy in Black and Latinx
502 Communities [Internet]. COVID Collaborative. 2020 [cited 2021 Jun 6]. Available
503 from: [https://www.covidcollaborative.us/content/vaccine-treatments/coronavirus-](https://www.covidcollaborative.us/content/vaccine-treatments/coronavirus-vaccine-hesitancy-in-black-and-latinx-communities)
504 [vaccine-hesitancy-in-black-and-latinx-communities](https://www.covidcollaborative.us/content/vaccine-treatments/coronavirus-vaccine-hesitancy-in-black-and-latinx-communities)
- 505 17. Ditekemena JD, Nkamba DM, Mutwadi A, Mavoko HM, Siewe Fodjo JN, Luhata
506 C, et al. COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A
507 Cross-Sectional Survey. *Vaccines* [Internet]. 2021 Feb 14;9(2):153. Available

- 508 from: <https://www.mdpi.com/2076-393X/9/2/153>
- 509 18. Tobin E, Okonofua M, Azeke A, Ajekweneh V, Akpede G. Willingness to
510 acceptance a COVID-19 vaccine in Nigeria: a population-based cross-sectional
511 study. *J Med Res*. 2021;5(2):1–6.
- 512 19. Monama T. 71% of South Africans are willing to take the COVID-19 vaccine
513 [Internet]. 2021. Available from:
514 [https://www.news24.com/news24/southafrica/news/71-of-south-africans-are-](https://www.news24.com/news24/southafrica/news/71-of-south-africans-are-willing-to-take-the-covid-19-vaccine-study-20210512)
515 [willing-to-take-the-covid-19-vaccine-study-20210512](https://www.news24.com/news24/southafrica/news/71-of-south-africans-are-willing-to-take-the-covid-19-vaccine-study-20210512)
- 516 20. Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X, et al. Global, regional, and
517 national estimates of target population sizes for covid-19 vaccination: descriptive
518 study. *BMJ* [Internet]. 2020 Dec 15;m4704. Available from:
519 <https://www.bmj.com/lookup/doi/10.1136/bmj.m4704>
- 520 21. Mavhunga C. Government urges Zimbabweans to accept COVID-19 Vaccine.
521 VOA News [Internet]. 2021 Feb 13; Available from:
522 [https://www.voanews.com/covid-19-pandemic/government-urges-zimbabweans-](https://www.voanews.com/covid-19-pandemic/government-urges-zimbabweans-accept-covid-19-vaccine)
523 [accept-covid-19-vaccine](https://www.voanews.com/covid-19-pandemic/government-urges-zimbabweans-accept-covid-19-vaccine)
- 524 22. Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ. Strategies for
525 addressing vaccine hesitancy – A systematic review. *Vaccine* [Internet]. 2015
526 Aug;33(34):4180–90. Available from:
527 <https://linkinghub.elsevier.com/retrieve/pii/S0264410X15005046>
- 528 23. Gayle H, Foege W, Brown L, Kahn B. Framework for Equitable Allocation of
529 COVID-19 Vaccine: Achieving Acceptance of COVID-19 Vaccine. National
530 Academies of Sciences, Engineering, and Medicine. 2020.

- 531 24. Shaw J, Stewart T, Anderson KB, Hanley S, Thomas SJ, Salmon DA, et al.
532 Assessment of US Healthcare Personnel Attitudes Towards Coronavirus Disease
533 2019 (COVID-19) Vaccination in a Large University Healthcare System. Clin
534 Infect Dis [Internet]. 2021 Jan 25; Available from:
535 <https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab054/6118651>
- 536 25. Mutambudzi M, Niedzwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et
537 al. Occupation and risk of severe COVID-19: prospective cohort study of 120 075
538 UK Biobank participants. Occup Environ Med [Internet]. 2021 May;78(5):307–14.
539 Available from: <https://oem.bmj.com/lookup/doi/10.1136/oemed-2020-106731>
- 540 26. Gur-Arie R, Jamrozik E, Kingori P. No Jab, No Job? Ethical Issues in Mandatory
541 COVID-19 Vaccination of Healthcare Personnel. BMJ Glob Heal [Internet]. 2021
542 Feb 17;6(2):e004877. Available from:
543 <https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2020-004877>
- 544 27. Africa Centres for Disease Control and Prevention, London School of Hygiene
545 and Tropical Medicine's Vaccine Confidence Project, Orb International. COVID 19
546 Vaccine Perceptions: A 15 country study. 2021;(February):1–70.
- 547 28. El-Elimat T, AbuAISamen MM, Almomani BA, Al-Sawalha NA, Alali FQ.
548 Acceptance and attitudes toward COVID-19 vaccines: A cross-sectional study
549 from Jordan. medRxiv [Internet]. 2020;(816):1–15. Available from:
550 <http://dx.doi.org/10.1371/journal.pone.0250555>
- 551 29. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al.
552 Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United
553 States. Vaccines [Internet]. 2020 Oct 3;8(4). Available from:

- 554 <http://www.ncbi.nlm.nih.gov/pubmed/33022917>
- 555 30. Shah A, Marks PW, Hahn SM. Unwavering Regulatory Safeguards for COVID-19
556 Vaccines. JAMA [Internet]. 2020 Sep 8;324(10):931. Available from:
557 <https://jamanetwork.com/journals/jama/fullarticle/2769421>
- 558 31. Everington K. Full list of adverse reactions from China's Sinopharm vaccine
559 revealed. Taiwan News [Internet]. 2021 Jan 11; Available from:
560 <https://www.taiwannews.com.tw/en/news/4098913>
- 561 32. Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev
562 Immunol [Internet]. 2020 Aug 17;20(8):451–2. Available from:
563 <http://www.nature.com/articles/s41577-020-0372-8>
- 564 33. Halabi S, Heinrich A, Omer SB. No-Fault Compensation for Vaccine Injury — The
565 Other Side of Equitable Access to Covid-19 Vaccines. N Engl J Med [Internet].
566 2020 Dec 3;383(23):e125. Available from:
567 <http://www.nejm.org/doi/10.1056/NEJMp2030600>
- 568 34. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM.
569 Attitudes Toward a Potential SARS-CoV-2 Vaccine. Ann Intern Med [Internet].
570 2020 Dec 15;173(12):964–73. Available from:
571 <https://www.acpjournals.org/doi/10.7326/M20-3569>
- 572 35. Soares P, Rocha JV, Moniz M, Gama A, Laires PA, Pedro AR, et al. Factors
573 associated with COVID-19 vaccine hesitancy. Vaccines. 2021;9(3):1–14.
- 574 36. Lazarus J V., Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO, et al. Hesitant or
575 Not? The Association of Age, Gender, and Education with Potential Acceptance
576 of a COVID-19 Vaccine: A Country-level Analysis. J Health Commun [Internet].

- 577 2020 Oct 2;25(10):799–807. Available from:
578 <https://www.tandfonline.com/doi/full/10.1080/10810730.2020.1868630>
- 579 37. CDC. Older Adults at greater risk of requiring hospitalization or dying if diagnosed
580 with COVID-19 [Internet]. Center for Disease Control and Prevention. 2021.
581 Available from: [https://www.cdc.gov/coronavirus/2019-ncov/need-extra-](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html)
582 [precautions/older-adults.html](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html)
- 583 38. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A
584 comparison with young and middle-aged patients. *J Infect* [Internet]. 2020
585 Jun;80(6):e14–8. Available from:
586 <https://linkinghub.elsevier.com/retrieve/pii/S016344532030116X>
- 587 39. Alqudeimat Y, Alenezi D, AlHajri B, Alfouzan H, Almokhaizeem Z, Altamimi S, et
588 al. Acceptance of a COVID-19 Vaccine and its Related Determinants among the
589 General Adult Population in Kuwait. *Med Princ Pract* [Internet]. 2021 Jan 22;
590 Available from: <https://www.karger.com/Article/FullText/514636>
- 591 40. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19
592 vaccine acceptance in the US. *EClinicalMedicine* [Internet]. 2020 Sep;26:100495.
593 Available from: <https://linkinghub.elsevier.com/retrieve/pii/S258953702030239X>
- 594 41. Wong LP, Alias H, Wong P-F, Lee HY, AbuBakar S. The use of the health belief
595 model to assess predictors of intent to receive the COVID-19 vaccine and
596 willingness to pay. *Hum Vaccin Immunother* [Internet]. 2020 Sep 1;16(9):2204–
597 14. Available from:
598 <https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1790279>
- 599 42. Mufunda E, Albin B, Hjelm K. Differences in Health and Illness Beliefs in

- 600 Zimbabwean Men and Women with Diabetes. *Open Nurs J* [Internet]. 2012 Aug
601 6;6:117–25. Available from: [http://benthamopen.com/ABSTRACT/TONURSJ-6-](http://benthamopen.com/ABSTRACT/TONURSJ-6-117)
602 117
- 603 43. CDC. COVID-19 Vaccines While Pregnant or Breastfeeding [Internet]. Center for
604 Disease Control and Prevention. 2021 [cited 2021 May 28]. Available from:
605 [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html)
606 [ncov/vaccines/recommendations/pregnancy.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html)
- 607 44. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al.
608 Genomic evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect*
609 *Dis* [Internet]. 2021;21(1):52–8. Available from: [http://dx.doi.org/10.1016/S1473-](http://dx.doi.org/10.1016/S1473-3099(20)30764-7)
610 [3099\(20\)30764-7](http://dx.doi.org/10.1016/S1473-3099(20)30764-7)
- 611 45. Abu-Raddad LJ, Chemaitelly H, Malek JA, Ahmed AA, Mohamoud YA,
612 Younuskunju S, et al. Assessment of the Risk of Severe Acute Respiratory
613 Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure
614 Setting. *Clin Infect Dis*. 2020;2.
- 615 46. Edridge E, Kaczorowska J, Hoste A, Baker M, Klein M, Loens K, et al. Seasonal
616 coronavirus protective immunity is short-lasting. *Nat Med*. 2020;11:1691–3.
- 617 47. McMahon A, Robb NC. Reinfection with SARS-CoV-2: Discrete SIR (Susceptible,
618 Infected, Recovered) Modeling Using Empirical Infection Data. *JMIR Public Heal*
619 *Surveill* [Internet]. 2020 Nov 16;6(4):e21168. Available from:
620 <http://publichealth.jmir.org/2020/4/e21168/>
- 621 48. Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, et al. Articles
622 SARS-CoV-2 seropositivity and subsequent infection risk in healthy young

623 adults: a prospective cohort study. *Lancet Respir [Internet]*. 2021;2600(21):1–9.

624 Available from: [http://dx.doi.org/10.1016/S2213-2600\(21\)00158-2](http://dx.doi.org/10.1016/S2213-2600(21)00158-2)

625 49. Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ.

626 COVID-19 Vaccination Hesitancy in the United States: A Rapid National

627 Assessment. *J Community Health [Internet]*. 2021 Apr 3;46(2):270–7. Available

628 from: <http://link.springer.com/10.1007/s10900-020-00958-x>

629 50. Ferdinand KC, Nedunchezian S, Reddy TK. The COVID-19 and Influenza

630 “Twindemic”: Barriers to Influenza Vaccination and Potential Acceptance of

631 SARS-CoV2 Vaccination in African Americans. *J Natl Med Assoc [Internet]*. 2020

632 Dec;112(6):681–7. Available from:

633 <https://linkinghub.elsevier.com/retrieve/pii/S0027968420304089>

634 51. Quinn SC, Jamison AM, Freimuth V. Communicating Effectively About

635 Emergency Use Authorization and Vaccines in the COVID-19 Pandemic. *Am J*

636 *Public Health [Internet]*. 2021 Mar;111(3):355–8. Available from:

637 <https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2020.306036>

638

639

640

641


Apart from yourself, how worried are you, if at all, about the possibility that some of your close friends or family members might catch the coronavirus?




How worried are you, if at all, about the possibility that you might catch the coronavirus?



How worried are you, if at all, about the possibility that you might catch the coronavirus again?



How severe was your case of the coronavirus?



0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%

■ Very ■ Somewhat ■ Not so ■ Not at all

